Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 124-127

  Parruti, Giustino ^a   Polilli, Ennio ^a   Sozio, Federica ^a   Cento, Valeria ^b   Pieri, Alessandro ^a   Di Masi, Francesco ^a   Mercurio, Fabio ^b   Tontodonati, Monica ^a   Mazzotta, Elena ^a   Ceccherini Silberstein, Francesca ^b   Manzoli, Lamberto ^c   Perno, Carlo Federico ^b  

^a Pescara General Hospital   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

Early SVR prediction; EVR prediction; HCV; HCV RNA decay; PEG IFN and ribavirin; Treatment

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE; VIREMIA;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA STABILITY; RNA, VIRAL; TREATMENT OUTCOME;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77956908092     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.08.003     Document Type: Article

References (13)

1. Arends J.E., Stuart C., Baak L.C., van der Ende M.E., van Erpecum K.J., Simons C.P.M., Boland G.J., van Baarle G., Hoepelman A.I.M. Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy. J. Viral. Hepat. 2009, 16:867-875.
2. Berg T., Sarrazin C., Herrmann E., Hinrichsen H., Gerlach T., Zachoval R., Wiedenmann B., Hopf U., Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003, 37:600-609.
3. Boulestin A., Kamar N., Sandres-Sauné K., Legrand-Abravanel F., Alric L., Vinel J.P., Rostaing L., Izopet J. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J. Med. Virol. 2006, 78:365-371.
4. Durante-Mangoni E., Zampino R., Portella G., Adinolfi L.E., Utili R., Ruggiero G. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin. Infect. Dis. 2009, 49:406-498.
5. Hoofnagle J.H., Seeff L.B. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 2006, 355:2444-2451.
6. Hoofnagle J.H., Wahed A.S., Brown R.S., Howell C.D., Belle S.H. Early changes in hepatitis C virus (HCV) levels in response to peginterferon and ribavirin treatment in patients with chronic HCV genotype 1 infection. J. Infect. Dis. 2009, 199:1112-1120. for the Virahep-C Study Group.
7. Jessner W., Gschwantler M., Steindl-Munda P., Hofer H., Watkins-Riedel T., Wrba F., Mueller C., Gangl A., Ferenci P. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 2001, 358:1241-1242.
8. Layden-Almer J.E., Cotler S.J., Layden T.J. Viral kinetics in the treatment of chronic hepatitis C. J. Viral. Hepat. 2006, 13:499-504.
9. McHutchinson J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo K., Dienstag J., Lee W.M., Mak C., Garaud J.J., Albrecht J.K. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069. for the International Hepatitis Interventional Therapy Group.
10. Nomura H., Miyagi Y., Tanimoto H., Higashi M., Ishibashi H. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J. Gastroenterol. 2009, 44:338-345.
11. Pascu M., Martus P., Höhne M., Wiedenmann B., Hopf U., Schreier E., Berg T. Sustained virologic response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004, 53:1345-1351.
12. Pereira A.A., Jacobson I.M. New and experimental therapies for HCV. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:403-411.
13. Shirakawa H., Matsumoto A., Joshita S., Komatsu M., Tanaka N., Umemura T., Ichijo T., Yoshizawa K., Kiyosawa K., Tanaka E. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008, 48:1753-1760. Nagano Interferon Treatment Research Group.